吉非替尼联合化疗治疗晚期非小细胞肺癌的疗效及对血清肿瘤标志物和不良反应的影响

Efficacy of gefitinib combined with chemotherapy in the treatment of advanced non-small cell lung cancer and its effect on serum tumor markers and adverse reactions

目的探讨吉非替尼联合化疗治疗晚期非小细胞肺癌的疗效及对血清肿瘤标志物和不良反应的影响。方法选取2019年2月至2020年2月本院收治的晚期非小细胞肺癌115例,按照随机数表法分为对照组(n=57)与观察组(n=58)。对照组行化疗(顺铂+吉西他滨)治疗,观察组在对照组基础上联合吉非替尼治疗。比较两组临床疗效、血清肿瘤标志物及不良反应发生情况。结果观察组治疗总有效率为98.28%,高于对照组的84.21%,差异有统计学意义(P<0.05)。治疗前,两组血清肿瘤标志物比较差异无统计学意义;治疗后,两组NSE、CYFRA21-1、CA19-9水平均低于治疗前,且观察组低于对照组(P<0.05)。观察组不良反应总发生率略低于对照组,但差异无统计学意义。结论吉非替尼联合化疗治疗晚期NSCLC效果显著,可有效降低患者血清肿瘤标志物,且未增加不良反应,值得临床推广应用。

Objective To investigate the efficacy of gefitinib combined with chemotherapy in the treatment of advanced non-small cell lung can-cer and its influence on serum tumor markers and adverse reactions.Methods 115 patients with advanced non-small cell lung cancer admitted to our hospital from February 2019 to February 2020 were selected and they were divided into control group(n=57)and observation group(n=58)accord-ing to the random number table method.The control group was treated with chemotherapy(cisplatin+gemcitabine),and the observation group was treated with gefitinib on the basis of the control group.The clinical efficacy,serum tumor markers and incidence of adverse reactions between the two groups were conpared.Results The total effective rate of the observation group was 98.28%,which was higher than 84.21%of the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in serum tumor markers be-tween the two groups;after treatment,the levels of NSE,CYFRA21-1 and CA19-9 in the two groups were lower than those before treatment,and the observation group was lower than the control group(P<0.05).The total incidence of adverse reactions in the observation group was slightly lower than that in the control group,but the difference was not statistically significant.Conclusion Gefitinib combined with chemotherapy has significant effect on the treatment of advanced NSCLC and can effectively reduce serum tumor markers in patients and without increasing adverse reactions,which is worthy of clinical application.